Mona Mohammadhosseini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mona Mohammadhosseini has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Anupriya Agarwal
Division of Oncological Sciences, Oregon Health & Science University, United States
27 shared publications - Alisa Damnernsawad
Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon
25 shared publications - Chelsea Hutchinson
Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA
25 shared publications - Christopher A. Eide
Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, USA
25 shared publications - Daniel Bottomly
Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA
25 shared publications - Guanming Wu
Oregon Health & Science University
25 shared publications
Latest Publications
- Top Cited Papers
- 8 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (780) , eadn9832
Targeting the CD74 signaling axis suppresses inflammation and rescues defective hematopoiesis in RUNX1 -familial platelet disorder
Familial platelet disorder (FPD) is associated with germline RUNX1 mutations, establishing a preleukemic state and increasing the risk of developing leukemia. Currently, there are no intervention strategies to prevent leukemia progression. Single-cell RNA sequencing ( n = 10) combined with functional analysis of samples from patients with RUNX1 -FPD ( n > 75) revealed that FPD hematopoietic stem and progenitor cells (HSPCs) displayed increased myeloid differentiation and suppressed megakaryopoiesis because of increased activation of prosurvival and inflammatory pathways. Bone marrow from patients with RUNX1 -FPD contained an elevated cytokine milieu, exerting chronic inflammatory stress on HSPCs. RUNX1 -FPD HSPCs were myeloid biased, had increased self-renewal, and were resistant to inflammation-mediated exhaustion. The bone marrow from patients with RUNX1 -FPD showed high transcript and protein expression of CD74 at the preleukemic stage compared with that of healthy controls, which remained high upon patient transformation into leukemia. Further, CD74-mediated signaling was exaggerated in RUNX1 -FPD HSPCs compared with healthy controls, leading to the activation of mTOR and JAK/STAT pathways with increased cytokine production. Genetic and pharmacological targeting of CD74 with ISO-1 and its downstream targets JAK1/2 and mTOR reversed RUNX1 -FPD differentiation defects in vitro and in vivo and reduced inflammation. Our results highlight that inflammation is an early event in RUNX1 -FPD pathogenesis, and CD74 signaling is one of the drivers of this inflammation. The repurposing of JAK1/2i (ruxolitinib) and mTORi (sirolimus) and promoting the advancement of CD74 inhibitors in clinical settings as an early intervention strategy would be beneficial to improve the phenotype of patients with RUNX1 -FPD and prevent myeloid progression.
- 8 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (780) , eadn9832
Top Cited PapersTargeting the CD74 signaling axis suppresses inflammation and rescues defective hematopoiesis in RUNX1 -familial platelet disorder
Familial platelet disorder (FPD) is associated with germline RUNX1 mutations, establishing a preleukemic state and increasing the risk of developing leukemia. Currently, there are no intervention strategies to prevent leukemia progression. Single-cell RNA sequencing ( n = 10) combined with functional analysis of samples from patients with RUNX1 -FPD ( n > 75) revealed that FPD hematopoietic stem and progenitor cells (HSPCs) displayed increased myeloid differentiation and suppressed megakaryopoiesis because of increased activation of prosurvival and inflammatory pathways. Bone marrow from patients with RUNX1 -FPD contained an elevated cytokine milieu, exerting chronic inflammatory stress on HSPCs. RUNX1 -FPD HSPCs were myeloid biased, had increased self-renewal, and were resistant to inflammation-mediated exhaustion. The bone marrow from patients with RUNX1 -FPD showed high transcript and protein expression of CD74 at the preleukemic stage compared with that of healthy controls, which remained high upon patient transformation into leukemia. Further, CD74-mediated signaling was exaggerated in RUNX1 -FPD HSPCs compared with healthy controls, leading to the activation of mTOR and JAK/STAT pathways with increased cytokine production. Genetic and pharmacological targeting of CD74 with ISO-1 and its downstream targets JAK1/2 and mTOR reversed RUNX1 -FPD differentiation defects in vitro and in vivo and reduced inflammation. Our results highlight that inflammation is an early event in RUNX1 -FPD pathogenesis, and CD74 signaling is one of the drivers of this inflammation. The repurposing of JAK1/2i (ruxolitinib) and mTORi (sirolimus) and promoting the advancement of CD74 inhibitors in clinical settings as an early intervention strategy would be beneficial to improve the phenotype of patients with RUNX1 -FPD and prevent myeloid progression.
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Suppl Table S10 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
CRISPR pathway enrichment analysis
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Table S10 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
CRISPR pathway enrichment analysis
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Supp Table S3 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
RNA-seq gene list and pathway correlation with drug resistance
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupp Table S3 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
RNA-seq gene list and pathway correlation with drug resistance
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Suppl Table S7 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
Phosphopeptides identified by trametinib and CCL2 treatments using a KSEA analysis
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Table S7 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
Phosphopeptides identified by trametinib and CCL2 treatments using a KSEA analysis
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Suppl Table S8 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
GSEA analysis from trametinib-sensitive and resistant cells
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Table S8 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
GSEA analysis from trametinib-sensitive and resistant cells
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Suppl Table S5 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
Suppl Table S5 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Table S5 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
Suppl Table S5 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Suppl Table S7 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
Phosphopeptides identified by trametinib and CCL2 treatments using a KSEA analysis
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Table S7 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
Phosphopeptides identified by trametinib and CCL2 treatments using a KSEA analysis
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Suppl Table S10 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
CRISPR pathway enrichment analysis
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Table S10 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
CRISPR pathway enrichment analysis
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
Suppl Figures 1-5 and list of tables 1-10
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
Suppl Figures 1-5 and list of tables 1-10